12TH INTERNATIONAL CONGRESS ON SPONDYLOARTHRITIDES …

INTERNATIONALCONGRESSON SPONDYLOARTHRITIDES

www.spa-congress.org

12TH

PROGRAMME

9 - 11 September 2021

www.spa-congress.org

Online Congress

12TH12TH

2 3www.spa-congress.org www.spa-congress.org

Organisation

PresidentRik Lories (Belgium)

Local Organising CommitteeDirk Elewaut (Belgium)

Filip Van den Bosch (Belgium)

Honorary Scientific CommitteeEric Veys (Belgium – Founder)

Herman Mielants (Belgium - Co-Founder)Paul Bowness (uK)

Jürgen Braun (Germany) Matthew Brown (Australia)

Robert Colbert (USA) Robert Inman (Canada)

Marjatta Leirisalo-Repo (Finland) Jose A. Lopez de Castro (Spain)

Désirée van der Heijde (The Netherlands) David Yu (USA)

Scientific CommitteeXenofon Baraliakos (Germany)

Maxime Breban (France)Rubén Burgos Vargas (Mexico)

Francesco Ciccia (Italy) Laura Coates (UK)

Maria-Antonietta D’Agostino (France) Atul Deodhar (USA)

Lianne Gensler (USA)Nigil Haroon (Canada)

Helena Marzo-Ortega (UK) Robert Landewé (The Netherlands)

Walter Maksymowych (Canada) John Reveille (USA)

Martin Rudwaleit (Germany) Percival Sampaio-Barros (Brazil)

Jose Scher (USA)Georg Schett (Germany)

Welcome Address

Dear colleagues and friends,

Unprecedented times… required unprecedented measures. Due to the worldwide pandemic, we were not be able to invite you all to the Twelfth International Congress on Spondyloarthritides in 2020, but will try to make it up now in September 2021.

The Belgian COVID-19 measures and internal rules of the University of Gent, allow us to welcome only a small number of participants to Gent. We therefore were forced to restrict the live congress to the Organising and Scientific Committees, the speakers and the sponsors, without whose support the organisation of this congress would not be possible.

However, we are pleased to announce that the congress will be livestreamed on an online platform where you and many international colleagues can tune in and view the talks in real-time or at a convenient time for a month after the congress dates. Furthermore, the platform will offer ample opportunity for networking.

The congress has grown over the years to become the premier international event in the field of the Spondylarthritides. The success of the Gent congress has been underpinned by the quality of the scientific contributions including the state-of-the-art lectures given by carefully chosen guest speakers and selected abstract presenters. To facilitate the organisation of a live event, the local and scientific organizers focused on excellent speakers from continental Western Europe. We have not forgotten our far-away friends and colleagues and hope to see you back in 2022 at the next full edition.

The programme for the 2021 congress will still offer a wide range of topics including basic and clinical translational research, genetics, imaging and therapeutics.

In 2018, the ‘Gent Oration’ was introduced, aimed to honor a scientist or clinician with an established trajectory in the field which we expect with time, to become one of the main highlights of the congress. It is our great pleasure to invite Professor Maxime Dougados as the inaugural Gent orator in this second edition.

We hope to welcome you and meet you online at the Tweltfth International Congress on Spondyloarthritides and remain,

Yours sincerely,

Rik Lories, PresidentDirk Elewaut and Filip Van den Bosch, Local Organisers


Thursday 9 September

12.50 Welcome Address Rik Lories, Congress President

SESSION 1: Pain, the next frontier in spondyloarthritis

13.00 INV1 The molecular basis of sensitization and pain Annemarie Malfait, USA

13.30 INV2 Pain and consequences for SpA patients Annelies Boonen, The Netherlands

SESSION 2: Spondyloarthritis in the post-genetics, pre-personalized medicine era

14.00 INV3 Could genetics be useful for clinical practice? Maxime Breban, France

14.25 INV4 Syndromes and rare disease, a toolkit for understanding spondyloarthritis Corinne Miceli, France

14.50 INV5 Opportunities for early remission in spondyloarthritis: A long-lasting effect? Philippe Carron, Belgium

15.15 Coffee Break and ePoster Viewing

SESSION 3: Spondyloarthritis in the post-genetics, pre-personalized medicine era

15.45 INV6 Crystals as activator of immunity Bart Lambrecht, Belgium

16.15 INV7 Neutrophils and NETS as orchestrators of chronic inflammatory disease Martin Herrmann, Germany

Thursday 9 September

Selected Oral Presentations I

16.45 O1 Comprehensive epigenomic profiling reveals disease- specific chromatin states in ankylosing spondylitis Carla Cohen, UK

17.00 O2 Phenotypic, histologic and imagiologic characterization of transmembrane tumor necrosis factor transgenic mice Elsa Vieira-Sousa, Portugal

17.15 O3 MHC haplotype controls development of IL-23 minicircle- induced murine spondyloarthritis Joerg Ermann, USA

Keynote Lecture - The Ghent SpA Oration17.30 INV8 A journey of discovery through axial spondyloarthritis Maxime Dougados, France

18.15 End of day 1


Friday 10 September

Session 4: Chasing the ghost: Disease modification in axSpA

08.30 INV9 The translational rheumatologist’s view Georg Schett, Germany

09.00 INV10 The absolutely correct way to assess Disease Modification in 2021 Robert Landewé, The Netherlands

09.30 INV11 Lessons learnt from studies of Disease Modification to optimally manage patients in the clinic Denis Poddubnyy, Germany


Selected Oral Presentations II

10.30 O4 The ASAS-OMERACT core domain set for axial spondyloarthirtis Victoria Navarro Compán, Spain

10.45 O5 Co-medication with a csDMARD is associated with improved outcomes of TNF inhibitors in patients with axial spondylarthritis: Results from the EuroSpA collaboration Michael Nissen, EuroSpA Research Collaboration, on behalf of DANBIO, Denmark

11.00 O6 Peripheral manifestations are major determinants of disease phenotype and outcome in new onset spondyloarthritis: Baseline and two-year follow-up data from the Be-GIANT cohort Ann-Sophie De Craemer, Belgium

11.15 O7 Functional genomics of RUNX3 regulatory SNPs associated with ankylosing spondylitis Matteo Vecellio, UK & Italy

11.30 O8 Th17 expansion is partially inhibited by IL-23, where polyfunctional Th17-derived cells are amplified by cellular stress in psoriatic arthritis Carmel Stober, UK

Friday 10 September

11.45 O9 Gut-joint migratory T cells are cytokine competent and contribute to inflammation in the joint Adam Lefferts, USA

12.00 Lunch

Session 5: Novel technologies and innovations in pathogenesis

13.30 INV12 New imaging tools in spondyloarthritis Connie van der Laken, The Netherlands

13.55 NV13 The deep dive – Single cell sequencing Martin Guilliams, Belgium

14.20 INV14 The data analyst: How to link clinical observations with new knowledge generation Rachel Knevel, The Netherlands

Selected Oral Presentations III

14.45 O10 Towards development of an ultrasound enthesitis score in psoriatic arthritis: 24-week results from the ULTIMATE study Maria-Antonietta D’Agostino, Italy

15.00 O11 Interleukin-23 inhibitors and their apparent ineffectiveness in treating axial spondyloarthritis: A systematic review with meta-analysis Louise Vanhoutte, Belgium

15.15 O12 A first in disease phase 2a trial of granulocyte monocyte colony stimulating factor neutralisation for axial spondyloarthritis (NAMASTE study) Paul Bowness, UK

15.30 O13 Metabolomics profiling of serum for biomarker discovery to identify psoriatic arthritis and ankylosing spondylitis Walter Maksymowych, Canada

15.45 O14 Dendritic cells influence T cell fate and pathogenicity in HLA-B27 transgenic rat model of spondyloarthritis Simon Glatigny, FranceFriday 10 September


Friday 10 September


Keynote Lecture – Basic Science16.30 INV15 Regulatory and memory T cells in immune-mediated disease Femke van Wijk, The Netherlands 17.15 End of day 2

Registration

Saturday 11 September

Session 6: Gut and SpA

08.30 INV16 Gut and SpA: New targets for treatment Francesco Ciccia, Italy

08.55 INV17 Fecal microbiota transplantation, lessons learned Speaker to be confirmed

09.20 INV18 Therapeutic impact of the microbiome, the IBD example Speaker to be confirmed

Selected Oral Presentations IV

09.45 O15 Factors associated with switching from one TNFi agent to another TNFi, or IL-17i agent in patients with ankylosing spondylitis John Reveille, USA

10.00 O16 Correspondence between patient-reported flare and disease activity score variation in axial spondyloarthritis Félicie Costantino, France

10.15 O17 CHOP deficiency does not prevent gut inflammation in experimental spondyloarthritis Fatemeh Navid, USA

10.30 O18 Novel use of specific drugs attenuates the pro-inflammatory cytokines IL-17A and IFN-gamma Rajinder Singh Andev, UK

10.45 O19 Neutrophil-derived MIF is a critical driver and potential therapeutic target in spondyloarthritis Akihiro Nakamura, Canada



Registration

Registration Fees Rates in EUR0Participant MD € 250,00Researcher non-MD* € 150,00 Medical student/resident* € 150,00Participant non-MD, industry participant € 400,00

*Immediately after signing up, send proof of your status to [email protected].

PaymentVisa, Mastercard and American Express are accepted.

Access to the Whova Event PlatformYou can use the event platform on desktop and on your smartphone. You will be notified when the event goes live.

RecordingsAll sessions will be recorded and added to the Whova Event Platform. So even if you are unable to tune in to the sessions in real-time, you can view them at any suitable time (up to one month after the congress dates).

Organisation and AdministrationMEDICONGRESSNoorwegenstraat 49B-9940 Evergem, BelgiumPhone: +32 (0)9 218 85 85Email: [email protected]

Saturday 11 September

Session 7: New interdisciplinary perspectives for spondyloarthritis

11.30 INV19 Emerging imaging techniques in spondyloarthritis: Dual- energy computed tomography and new MRI sequences Lennart Jans, Belgium

11.55 INV20 Impact of comorbidities on clinical management Ennio Lubrano, Italy

12.20 INV21 In silico medicine – Beyond the frontier Liesbet Geris, Belgium

12.45 Closure of the Congress Rik Lories, Congress President

Platinum Sponsors

Gold Sponsor

Silver Sponsor

Documents

12TH INTERNATIONAL CONGRESS ON SPONDYLOARTHRITIDES …